Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.61 |
| ▸ | MGLL | Q99685 | 3/20 | 0.60 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.50 |
| ▸ | HCAR2 | Q8TDS4 | 3/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.48 |
| ▸ | LTC4S | Q16873 | 1/20 | 0.48 |
| ▸ | NAAA | Q02083 | 1/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5055502 | 0.89 | NPC1 (0.58) | PTPN1MGLLENPP2NPC1RAB9A | |
| SCHEMBL6161722 | 0.88 | MGLL (0.56) | PTPN1MGLLENPP2NPC1RAB9A | |
| SCHEMBL14413323 | 0.84 | LTC4S (0.67) | MGLLENPP2NPC1RAB9AHDAC1 | |
| SCHEMBL3496550 | 0.83 | NPC1 (0.58) | MGLLNPC1RAB9AHDAC1HDAC2 | |
| SCHEMBL27608697 | 0.83 | ENPP2 (0.65) | PTPN1MGLLENPP2NPC1RAB9A | |
| SCHEMBL27772672 | 0.82 | NPC1 (0.55) | MGLLENPP2NPC1RAB9AHDAC1 | |
| SCHEMBL3793285 | 0.82 | MGLL (0.63) | PTPN1MGLLENPP2NPC1RAB9A | |
| SCHEMBL27608693 | 0.81 | MGLL (0.54) | MGLLENPP2NPC1RAB9AHDAC1 | |
| SCHEMBL1131165 | 0.81 | CASP3 (0.61) | MGLLNPC1RAB9ASERPINE1 | |
| SCHEMBL26030821 | 0.81 | CASP3 (0.62) | MGLLNPC1RAB9AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1379516-B1 | ALKOXYCARBONYLAMINO BENZOIC ACID OR ALKOXYCARBONYLAMINO TETRAZOLYL PHENYL DERIVATIVES AS IP ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2005-11-16 | — | — | EP | disclosed |
| US-6903086-B2 | Alkoxycarbonylamino benzoic acid or alkoxycarbonylamino tetrazolyl phenyl derivatives as IP antagonists | SYNTEX (U.S.A.) LLC (US) | 2005-06-07 | — | — | US | disclosed |
| CN-1527824-A | Alkoxycarbonylamino benzoic acid or alkoxycarbonylamino tetrazolyl phenyl derilatives as IP antagonists | - | 2004-09-08 | — | — | CN | disclosed |
| EP-1379516-A1 | ALKOXYCARBONYLAMINO BENZOIC ACID OR ALKOXYCARBONYLAMINO TETRAZOLYL PHENYL DERIVATIVES AS IP ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-01-14 | — | — | EP | disclosed |
| US-20020165235-A1 | Alkoxycarbonylamino benzoic acid or alkoxycarbonylamino tetrazolyl phenyl derivatives as IP antagonists | SYNTEX (U.S.A.) LLC | 2002-11-07 | — | — | US | disclosed |
| WO-2002070500-A1 | ALKOXYCARBONYLAMINO BENZOIC ACID OR ALKOXYCARBONYLAMINO TETRAZOLYL PHENYL DERIVATIVES AS IP ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2002-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020165235-A1 | Alkoxycarbonylamino benzoic acid or alkoxycarbonylamino tetrazolyl phenyl derivatives as IP antagonists | GPBAR1, GABRP, TBXA2R | PTPN1 460/4885MGLL 1914/4885ENPP2 327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.